StockNews.AI
DTIL
StockNews.AI
13 days

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

1. Precision BioSciences announced ELIMINATE-B trial results and initial safety data. 2. Data includes completed Cohort 1 and initial findings from Cohort 2.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results often boost investor confidence; previous positive biotech trials resulted in price surges.

How important is it?

The announcement of trial results is critical for potential FDA approval and market strategy.

Why Long Term?

Successful trial outcomes can indicate future revenue potential and market growth for DTIL.

Related Companies

CRSPEDITNTLA
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, announced ELIMINATE-B results as of the data cutoff of July 28, 2025. Data include completed Cohort 1 (dosed at 0.2 mg/kg), the lowest dose level of the ELIMINATE-B trial, and initial safety data from Cohort 2 (dosed at 0.4 mg/kg). The ELIMINATE-B trial is designed.

Related News